VVP
MYGN icon

Venture Visionary Partners’s Myriad Genetics MYGN Stock Holding History

Venture Visionary Partners’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-500
Closed -$9.09K – 1154
2022
Q2 		$9.09K Buy
+500
New +$10.4K ﹤0.01% 1269

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Venture Visionary Partners's MYGN Position: Q3 2022 in Review

Venture Visionary Partners sold out of Myriad Genetics (MYGN) in Q3 2022, closing a stake of 500 shares — an estimated $9.09K sold.

Venture Visionary Partners first reported a position in MYGN in Q2 2022 and held it in 1 quarter. The position peaked at $9.09K in Q2 2022. 191 funds tracked by Wall St. Rank hold MYGN as of Q3 2022.

  • Venture Visionary Partners reported no remaining Myriad Genetics position as of Q3 2022 after selling out during the quarter.
  • Venture Visionary Partners sold 500 Myriad Genetics shares in Q3 2022, an estimated $9.09K.
  • Venture Visionary Partners first reported a position in Myriad Genetics in Q2 2022 and held it in 1 quarter.
  • Venture Visionary Partners's Myriad Genetics position peaked at $9.09K in Q2 2022.
  • 191 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2022.

Based on Venture Visionary Partners's 13F filing for Q3 2022, filed 14 Nov 2022.